Abstract

Drug-eluting stent (DES) design features, including strut thickness, can influence the biological response to percutaneous coronary intervention (PCI). Recent studies suggest the clinical superiority of an ultrathin strut (60 microns), biodegradable-polymer, sirolimus-eluting stent (Orsiro; Biotronik, Berlin, Germany) over a thin-strut (81 microns), permanent-polymer, everolimus-eluting stent (Xience; Abbott, Chicago, IL, USA) in ST elevation myocardial infarction (STEMI) patients undergoing PCI.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call